These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34753336)

  • 1. Parent Perceptions in Choosing Treatment for Infants With Spinal Muscular Atrophy Diagnosed Through Newborn Screening.
    Deng S; Lee BH; Ciafaloni E
    J Child Neurol; 2022 Jan; 37(1):43-49. PubMed ID: 34753336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1.
    Nanri D; Yuge K; Goto K; Kimura T; Yae Y; Mizuochi T; Sato R; Itonaga T; Maeda T; Yamashita Y
    Kurume Med J; 2024 May; 69(3.4):255-259. PubMed ID: 38233181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy.
    Chiang J; Xiao L; Nigro E; St-Laurent A; Weinstock L; Law E; Janevski J; Kuyntjes S; Cithiravel N; Tran T; Wolter NE; Gonorazky H; Amin R;
    Sleep Med; 2023 Nov; 111():161-169. PubMed ID: 37778092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Therapy of Spinal Muscular Atrophy.
    Klotz J; Tesi Rocha C; Dunaway Young S; Duong T; Buu M; Sampson J; Day JW
    J Pediatr; 2021 Sep; 236():13-20.e1. PubMed ID: 34197889
    [No Abstract]   [Full Text] [Related]  

  • 5. Parental Experiences with Newborn Screening and Gene Replacement Therapy for Spinal Muscular Atrophy.
    Meyer AP; Connolly AM; Vannatta K; Hacker N; Hatfield A; Decipeda A; Parker P; Willoughby A; Waldrop MA
    J Neuromuscul Dis; 2024; 11(1):129-142. PubMed ID: 38160362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophy.
    Wood MF; Hughes SC; Hache LP; Naylor EW; Abdel-Hamid HZ; Barmada MM; Dobrowolski SF; Stickler DE; Clemens PR
    Muscle Nerve; 2014 Jun; 49(6):822-8. PubMed ID: 24307279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency.
    Butterfield RJ
    Semin Pediatr Neurol; 2021 Jul; 38():100899. PubMed ID: 34183144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 9. Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.
    Gaillard J; Gu AR; Neil Knierbein EE
    J Pediatr; 2023 Sep; 260():113493. PubMed ID: 37211209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study.
    Kariyawasam DS; D'Silva AM; Sampaio H; Briggs N; Herbert K; Wiley V; Farrar MA
    Lancet Child Adolesc Health; 2023 Mar; 7(3):159-170. PubMed ID: 36669516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening.
    Glascock J; Sampson J; Haidet-Phillips A; Connolly A; Darras B; Day J; Finkel R; Howell RR; Klinger K; Kuntz N; Prior T; Shieh PB; Crawford TO; Kerr D; Jarecki J
    J Neuromuscul Dis; 2018; 5(2):145-158. PubMed ID: 29614695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy.
    Lee BH; Waldrop MA; Connolly AM; Ciafaloni E
    Muscle Nerve; 2021 Aug; 64(2):153-155. PubMed ID: 33959970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1.
    Oechsel KF; Cartwright MS
    Muscle Nerve; 2021 Oct; 64(4):487-490. PubMed ID: 34287987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience.
    Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J
    J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
    Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
    Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
    Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Access to orphan drugs for the treatment of spinal muscular atrophy in Spain].
    García-Parra B; Guiu JM; Modamio P; Martínez-Yélamos A; Mariño-Hernández EL; Povedano M
    Rev Neurol; 2022 Nov; 75(9):261-267. PubMed ID: 36285446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening.
    Weng WC; Hsu YK; Chang FM; Lin CY; Hwu WL; Lee WT; Lee NC; Chien YH
    Genet Med; 2021 Feb; 23(2):415-420. PubMed ID: 33033402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy.
    Lee S; Lee YJ; Kong J; Ryu HW; Shim YK; Han JY; Woo H; Kim SY; Cho A; Lim BC; Chae JH
    Brain Dev; 2022 Apr; 44(4):287-293. PubMed ID: 35033405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.